Three-Class Antiretroviral Therapy for HIV Not Appropriate: Results from the FIRST Study
RODGER MACARTHUR, Wayne State University, Detroit
REFERENCE: Lancet 2006; 368: 2125-35
A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST study had three arms which included non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or both, all in the presence of nucleoside reverse transcriptase inhibitors. Derek Thorne heard more from Rodger MacArthur of Wayne State University in Detroit.
[audio:https://www.audiomedica.com/podcasting/global_health/070117rodger_macarthur.mp3]A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST study had three arms which included non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or both, all in the presence of nucleoside reverse transcriptase inhibitors. Derek Thorne heard more from Rodger MacArthur of Wayne State University in Detroit.
